drugset / Trial / NCT00878878

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

NCT00878878

Phase 4 Completed 30 enrolled GE Healthcare ICON Clinical Research · collab
RandomizedCrossoverSingle-blindDiagnostic

Summary

The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.

Timeline

Start
2009-03
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Optison Diagnostic / imaging agent 0.5 ml Intravenous